These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 6810911

  • 21. Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
    Landolfi R, de Cristofaro R, Lazzareschi I, Riccardi R, Mariani G.
    Haematologica; 2000 Oct; 85(10 Suppl):73-4. PubMed ID: 11187877
    [Abstract] [Full Text] [Related]

  • 22. Factor VIII inhibitors. Potential for prevention of inhibitor formation by immune tolerance.
    Kaplan J, Genyea C, Secord E.
    Semin Thromb Hemost; 2000 Oct; 26(2):173-8. PubMed ID: 10919410
    [Abstract] [Full Text] [Related]

  • 23. Factor VIII and factor IX inhibitors in haemophiliacs.
    Ignacio Lorenzo J, Garcia R, Molina R.
    Lancet; 1992 Jun 20; 339(8808):1550-1. PubMed ID: 1351235
    [No Abstract] [Full Text] [Related]

  • 24. The suppression of factor VIII antibodies in haemophilia.
    Dormandy KM, Sultan Y.
    Pathol Biol (Paris); 1975 Dec 20; 23 suppl():17-23. PubMed ID: 772555
    [Abstract] [Full Text] [Related]

  • 25. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.
    Smith MP, Spence KJ, Waters EL, Beresford-Webb R, Mitchell MJ, Cuttler J, Alhaq A, Brown SA, Savidge GF.
    Thromb Haemost; 1999 Jan 20; 81(1):35-8. PubMed ID: 9974371
    [Abstract] [Full Text] [Related]

  • 26. Differential prevalence of antibody to AIDS-associated retrovirus in haemophiliacs treated with Factor VIII concentrate versus cryoprecipitate: recovery of infectious virus.
    Koerper MA, Kaminsky LS, Levy JA.
    Lancet; 1985 Feb 02; 1(8423):275. PubMed ID: 2857339
    [No Abstract] [Full Text] [Related]

  • 27. [Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor].
    Scharf R, Kucharski W, Lopaciuk S, Celińska W, Dmytrow A, Domański K, Gonet S, Miastkowski Z, Nowakowska I, Przybylski A.
    Acta Haematol Pol; 1991 Feb 02; 22(1):92-9. PubMed ID: 1823972
    [Abstract] [Full Text] [Related]

  • 28. [Inhibitors (antibodies) directed against factor VIII in hemophilia A (author's transl)].
    Beck EA.
    Ther Umsch; 1979 Apr 02; 36(4):326-9. PubMed ID: 377556
    [No Abstract] [Full Text] [Related]

  • 29. Alterations in T-lymphocyte subsets among Danish haemophiliacs: relation to source of factor VIII preparations and high dose factor VIII treatment.
    Gerstoft J, Bentsen K, Scheibel E, Dalsgård-Nielsen J, Gormsen J, Dickmeiss E.
    Scand J Haematol; 1984 May 02; 32(5):544-51. PubMed ID: 6328639
    [Abstract] [Full Text] [Related]

  • 30. Preliminary trial of cyclophosphamide in the management of hemophiliacs with factor VIII inhibitors.
    Ruggeri ZM, Mannucci PM, Allain JP, Frommel D.
    Ann N Y Acad Sci; 1975 Jan 20; 240():412-8. PubMed ID: 1053886
    [No Abstract] [Full Text] [Related]

  • 31. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
    Sultan Y, White GC, Aronstam A, Bosser C, Brackmann HH, Brochier G, Gormsen J, Mariani G, Roberts HR, Scarabin Y.
    Nouv Rev Fr Hematol (1978); 1986 Jan 20; 28(2):85-9. PubMed ID: 3090516
    [Abstract] [Full Text] [Related]

  • 32. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C, Kurnik K, Escuriola-Ettingshausen C, Jager R, Klamroth R, Male C, Marosi A, Nemes L, von Stackelberg A, Kreuz W.
    Haemophilia; 2011 Sep 20; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract] [Full Text] [Related]

  • 33. Circulating antibodies in factor VIII deficiency hemophilia: report of case.
    Cudzinowski L.
    ASDC J Dent Child; 1979 Sep 20; 46(1):54-6. PubMed ID: 283081
    [No Abstract] [Full Text] [Related]

  • 34. The incidence of inhibitors in hemophilia A and the induction of immune tolerance.
    Briët E, Peters M.
    Adv Exp Med Biol; 2001 Sep 20; 489():89-97. PubMed ID: 11554594
    [No Abstract] [Full Text] [Related]

  • 35. Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia.
    Hruby MA, Schulman I.
    Blood; 1973 Dec 20; 42(6):919-23. PubMed ID: 4759918
    [No Abstract] [Full Text] [Related]

  • 36. Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs.
    Messori A, Longo G, Morfini M, Cinotti S, Filimberti E, Giustarini G, Rossi Ferrini P.
    Eur J Clin Pharmacol; 1988 Dec 20; 35(6):663-8. PubMed ID: 3148473
    [Abstract] [Full Text] [Related]

  • 37. Strategies for reducing inhibitor formation in severe haemophilia.
    Tunstall O, Astermark J.
    Eur J Haematol; 2015 Feb 20; 94 Suppl 77():45-50. PubMed ID: 25560794
    [Abstract] [Full Text] [Related]

  • 38. [Factor VIII inhibitor in multitransfused hemophiliacs. A finding of varying therapeutic consequences].
    Ly B, Evensen SA, Stavem P.
    Tidsskr Nor Laegeforen; 1977 Apr 30; 97(12):554-6, 8. PubMed ID: 854906
    [No Abstract] [Full Text] [Related]

  • 39. Immune response induced by porcine factor VIII in severe hemophiliacs with antibody to F VIII.
    Verroust F, Allain JP.
    Thromb Haemost; 1982 Oct 29; 48(2):238. PubMed ID: 6817447
    [No Abstract] [Full Text] [Related]

  • 40. The natural history of factor VIII inhibitors in patients with hemophilia A.
    Gill FM.
    Prog Clin Biol Res; 1984 Oct 29; 150():19-29. PubMed ID: 6431427
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.